| Trial ID: | L1299 |
| Source ID: | NCT03093740
|
| Associated Drug: |
Zepatier
|
| Title: |
Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Renal Failure Chronic|Hepatitis C
|
| Interventions: |
DRUG: Zepatier|DRUG: Zepatier plus Sofosbuvir
|
| Outcome Measures: |
Primary: Undetectable HCV RNA, Negative HCV viral load 12 weeks after last dose of treatment, 12 weeks post treatment |
|
| Sponsor/Collaborators: |
Sponsor: Massachusetts General Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2018-10-01
|
| Completion Date: |
2021-01-31
|
| Results First Posted: |
|
| Last Update Posted: |
2018-12-20
|
| Locations: |
Massachusetts General Hospital, Boston, Massachusetts, 02114, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03093740
|
